Answers are grounded in this paper and cite their sources.
Meta-analysis demonstrates elevated IBI correlates with poorer survival in gastrointestinal cancer, suggesting its clinical relevance.
Background The Inflammatory Burden Index (IBI) has been identified as a significant prognostic factor in various gastrointestinal (GI) malignancies. However, despite extensive research, its prognostic value remains inconsistent. To clarify this association, we conducted a systematic meta-analysis following rigorous methodological standards.Methods A comprehensive literature search was performed across PubMed, Web of Science, Embase, Scopus, and Cochrane databases. Ultimately, nine studies were included, covering multiple gastrointestinal cancer subtypes.Results Our analysis demonstrated that an elevated IBI was significantly associated with poorer overall survival (OS) (HR = 2.14, 95% CI: 1.38–3.31, p = 0.001), disease-free survival (DFS) (HR = 1.75, 95% CI: 1.35–2.26, p < 0.001), and recurrence-free survival (RFS) (HR = 2.15, 95% CI: 1.59–2.92, p < 0.001). Furthermore, IBI levels were significantly correlated with several key clinicopathological factors including age, tumor size, lymph node metastases, lymph-vascular invasion, and neoadjuvant chemotherapy.Conclusion This meta-analysis suggests that elevated IBI might be a robust predictor for poor survival in GI cancer patients and correlates closely with advanced disease features including larger tumor size, lymph node metastases, and lymph-vascular invasion. These findings underscore IBI as a clinically relevant prognostic biomarker for GI malignancies.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: